Subscribe

We’ve Been Told To Take A “wait & See” Approach With Regards To The New NMPA Guidelines To Bypass Full Clinical Investigations For A New Ventilator. Are You Also In Line With A More “relaxed” Stance For CER Coming From The Latest NMPA Guidelines?

2021-10-18

I would encourage you to use the decision-making process flowchart, then you will be super clear where you are. You can make your own decision.

Suggested Reading

Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation?
GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests…
What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can…
Do all medical devices require chemical characterization?
How should the evaluation of new items in the endpoint table be considered after the implementation of the new…
Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,…
What factors may affect biocompatibility risk when using biological test data from similar devices for…
GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which…
When combining subchronic and implantation tests in one project, what factors need to be considered, and how can…

Previous: Are clinical evaluations required for products already approved or is this requirement only for new products?

Next: You mentioned effectiveness in some slides, but then focused on Performance and also mentioned patient benefit for CER; could you please clarify what the key requirements are?